Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Preferred Stock Liabilities (2023 - 2024)

Historic Preferred Stock Liabilities for Contineum Therapeutics (CTNM) over the last 2 years, with Q1 2024 value amounting to $192.6 million.

  • Contineum Therapeutics' Preferred Stock Liabilities changed N/A to $192.6 million in Q1 2024 from the same period last year, while for Mar 2024 it was $192.6 million, marking a year-over-year change of. This contributed to the annual value of $192.6 million for FY2023, which is N/A changed from last year.
  • Latest data reveals that Contineum Therapeutics reported Preferred Stock Liabilities of $192.6 million as of Q1 2024.
  • Over the past 5 years, Contineum Therapeutics' Preferred Stock Liabilities peaked at $192.6 million during Q4 2023, and registered a low of $192.6 million during Q4 2023.